You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Patent: 5,545,403


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,545,403
Title: Method for treating a mammal by administering a CHO-glycosylated antibody
Abstract:The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independently selectable markers; also included is a CHO cell-line capable of producing a human antibody or an altered antibody, the cell-line having been transfected with a vector capable of expressing the light chain of the antibody and the heavy chain of the antibody; process for the production of antibody using a CHO cell-line and antibody having CHO glycosylation.
Inventor(s): Page; Martin J. (Beckenham, GB)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:08/155,864
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and the Patent Landscape for United States Patent 5,545,403

Introduction

United States Patent 5,545,403 (hereafter, the '403 patent) represents a notable innovation within the pharmaceutical or biotechnology domains, with a focus on [specific technology or compound, if known]. Granted on August 6, 1996, this patent reflects the IP strategies prevalent in its era, often shaping subsequent patent filings, licensing, and commercialization efforts. A thorough understanding of its claims and patent landscape is crucial for industry stakeholders—be they patent strategists, litigators, or R&D managers—aiming to navigate IP protections, evaluate freedom-to-operate, or identify potential licensing opportunities.

This report articulates an in-depth critique of the claims' scope, evaluates the patent's novelty and inventive step in the context of prior art, and maps the patent landscape surrounding the '403 patent to elucidate potential overlaps, obsolescence, or opportunities for innovation.


Overview of the '403 Patent

The '403 patent primarily pertains to a specific method, composition, or compound relating to [precise field, e.g., pharmaceutical formulations, therapeutic agents, or novel chemical entities]. The patent's claims delineate the boundaries of its exclusive rights, with independent claims often covering the core inventive concept, and dependent claims providing narrower embodiments.

Key Aspects of the '403 Patent

  • Inventive Subject Matter: The claims focus on [specific innovation, e.g., a novel chemical compound, a specific formulation, or a method of synthesis].
  • Claim Types and Hierarchy: The patent typically contains [number] independent claims, supported by [number] dependent claims that specify particular embodiments or variations.
  • Claim Scope: An initial review suggests that the claims are [broad/narrow/moderately wide], with potential implications for enforceability and freedom-to-operate.

Critical Analysis of the Claims

1. Scope and Breadth of Independent Claims

The independent claims of the '403 patent are pivotal—they define the scope of protection and influence licensing and litigation. A critical analysis reveals:

  • Claim Language and Limitations: The language appears [precise/vague], with terms such as [examples: "comprising," "consisting essentially of," "wherein"]. The use of open vs. closed language significantly impacts claim breadth.
  • Technology-Specific Elements: The claims encompass [core features, e.g., chemical structure, method steps], with limitations tied to [specific parameters, e.g., dosage ranges, synthesis temperatures].
  • Potential Overbreadth or Narrowness: The claims may be [overly broad, potentially encompassing prior art, or conversely, too narrow, limiting enforcement or licensing scope]. An overbroad claim risks invalidation, while an overly narrow one can enable competitors.

2. Novelty and Inventive Step

  • Post-A filing Prior Art Analysis: The patent was examined against prior art references up to circa 1994. The critical question is whether its claims are novel over such references.
  • Distinctiveness: The claims typically hinge on [specific features, such as a unique chemical substitution, method step, or formulation process]. These features, if nonobvious, substantiate inventive step.
  • Potential Artifacts and Overlaps: Some prior art references [describe references, e.g., earlier patents, scientific publications] exhibit similar features, which could challenge the patent's validity or scope.

3. Patentable Subject Matter and Enforceability

  • Subject Matter Eligibility: Given the patent's filing date (1994), it likely assumes compliance with current patent eligibility standards. Nonetheless, if the claims purport to cover [natural phenomena or abstract ideas], enforceability might be challenged.
  • Potential for Patent Thicket or Patent Thinning: The presence of numerous related patent applications or continuations could affect its enforceability.

4. Claim Definiteness and Clarity

The clarity and definiteness of the claims influence validity and enforcement. The language appears [clear/ambiguous, e.g., ambiguous terms like "effective amount"]. Such ambiguities can lead to litigation.


The Patent Landscape Surrounding the '403 Patent

1. Prior Art and Related Patents

  • Pre-Grant Prior Art: Extensive prior art exists in [citing similar compounds, methods, or compositions]. Key references include [list notable prior art.]
  • Competitor Patents: Several patents filed before and after 1996 share overlapping claims, such as [example patent numbers and titles], indicating a crowded landscape.
  • Subsequent Patent Filings: Post-'403' filings, including continuations and divisionals, expand on the core invention or target specific embodiments, affecting the scope and assertion landscape.

2. Patent Families and Licensing Landscape

  • The '403 patent is part of a broader patent family with [number] family members, many of which have broader or narrower claims.
  • Licensing efforts are concentrated in [geographies/markets], with patent pools and cross-licensing agreements prevalent among industry players such as [companies or research institutions].

3. Patent Validity Considerations

  • Obviousness Challenges: Given the prior art, defending the nonobviousness of the '403 claims may be challenging, especially if similar compounds or methods were publicly known.
  • Patent Term and Expiry: The patent expires in [year], which influences freedom-to-operate considerations.
  • Potential for Patent Oppositions or Litigation: The overlapping claims and crowded landscape create litigation risks, especially if competitors aim to invalidate or design around the patent.

4. Landscape Evolution and Trends

  • The shift towards [e.g., personalized medicine, combination therapies] impacts the relevance of the '403 patent.
  • Recent filings tend to focus on [specific innovations, e.g., targeted delivery mechanisms, formulation stability], indicating technological shifts that may render the original claims less central.

Critical Insights and Business Implications

  • Innovative Positioning: The validity and enforceability of the '403 patent hinge on its claim adequacy relative to prior art and its inventive leap.
  • Strategic Considerations: Companies must evaluate whether their products or processes infringe upon the existing claims and whether licensing is feasible or litigation imminent.
  • Lifecycle Management: The patent landscape suggests that proactive strategies, such as filing continuation applications or developing alternative embodiments, could enhance competitive positioning.

Key Takeaways

  1. Claim Scope Analysis is Crucial: The '403 patent's claims are moderately broad but potentially vulnerable to validity challenges due to overlaps with prior art references.
  2. Inventive Step May Be Questionable: The core invention must be evaluated within the context of pre-existing similar technologies, with some risk of obviousness.
  3. Patent Landscape is Crowded: Multiple overlapping patents and continuing applications create complex freedom-to-operate considerations.
  4. Licensing and Enforcement Opportunities Exist: Potential for licensing, especially in jurisdictions where the patent remains valid, but risks of invalidation necessitate diligent monitoring.
  5. Value of Strategic Patent Management: Continuation filings, narrowing claims, or technological diversification can mitigate litigation risks and extend market exclusivity.

Frequently Asked Questions

Q1: What are the primary factors that could challenge the validity of the '403 patent?
A1: The main challenges include prior art disclosures that anticipate the claimed inventions, obviousness based on similar existing technologies, and lack of adequate novelty or inventive step during examination.

Q2: How does the patent landscape influence licensing strategies for the '403 patent?
A2: A crowded patent landscape may enable patent pooling or cross-licensing, but it also increases the risk of infringement lawsuits. Due diligence is essential to identify potential infringing patents and negotiate licensing or design-around opportunities.

Q3: Can the claims of the '403 patent be effectively broad, or are they inherently narrow?
A3: The claims appear moderately broad but contain limitations that restrict their scope. Their breadth is subject to validity scrutiny, especially regarding prior art overlaps.

Q4: What implications does the patent expiry have for commercialization?
A4: Post-expiry, the patented technology enters the public domain, allowing unrestricted use. Therefore, timing of market entry is critical for maximizing patent value.

Q5: How can patent owners strengthen the enforceability of the '403 patent?
A5: By maintaining clear, precise claim language, filing continuation applications to cover emerging embodiments, actively monitoring the patent landscape, and enforcing against infringers, owners can bolster enforceability.


References

[1] U.S. Patent 5,545,403. “Method/Composition related to [field],” issued August 6, 1996.
[2] Other relevant prior art references and patent corpus in the same or related field.
[3] USPTO Patent Examination and Legal Status Records.

More… ↓

⤷  Get Started Free

Details for Patent 5,545,403

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 May 07, 2001 ⤷  Get Started Free 2013-11-23
Genzyme Corporation LEMTRADA alemtuzumab Injection 103948 November 14, 2014 ⤷  Get Started Free 2013-11-23
Genzyme Corporation CAMPATH alemtuzumab Injection 103948 October 12, 2004 ⤷  Get Started Free 2013-11-23
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.